Ozoralizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| Chemical and physical data | |
| Formula | C1682H2608N472O538S12 |
| Molar mass | 38.43 kDa g·mol−1 |
  (what is this?) (verify) | |
Ozoralizumab is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.
Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV.
References
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |